October 12, 2026 05:58 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'Undeclared Emer-GenZ': Shashi Tharoor slams Delhi curbs over CJP protests, calls internet shutdown 'most regressive' | ‘Bharat Mata Ki Jai’, ‘Inquilab Zindabad’: CJP leader Abhijeet Dipke dares Delhi Police to arrest him, says ‘We are not afraid’ | CJP protest crackdown? Abhijeet Dipke, Saurav Das and Ashutosh Ranka detained from inside flight | Dhruv Rathee detained ahead of CJP protests against CEC Gyanesh Kumar as Delhi goes on high alert | ‘Restriction, not complete closure’: Supreme Court questions Delhi shutdown ahead of CJP protest | 'Unwarranted': India hits back at JD Vance over ‘indentured servants’ remark amid US Green Card crackdown | US targets Microsoft, Infosys, Tata in green card crackdown | ‘Bold and inventive’: Canadian poet Anne Carson wins 2026 Nobel Prize in Literature | ‘Attempt to destabilise world’s largest democracy’: 42 retired judges rally behind Gyanesh Kumar over ‘vote chori’ row | ‘Vote chor, gaddi chod’: Dhruv Rathee, Prakash Raj join Bengaluru protest against Gyanesh Kumar
Johnson And Johnson Vaccine

Johnson & Johnson suspends COVID-19 vaccine trials in Brazil

| @indiablooms | Oct 14, 2020, at 02:54 pm

Brasilia/Xinhua: The Janssen-Cilag company, the pharmaceutical division of US multinational Johnson & Johnson, temporarily suspended clinical trials in Brazil of a vaccine against the novel coronavirus (COVID-19), the national health regulatory body Brazilian Health Surveillance Agency (Anvisa) said on Wednesday.

Janssen-Cilag notified Anvisa that testing to determine the safety and efficacy of its vaccine VAC31518COV3001 "was temporarily suspended due to a serious adverse occurrence in a volunteer abroad."

The company did not provide more details about the case, as the volunteer's health status is kept confidential.

According to Anvisa, the trials will not resume until there is an investigation into the cause of the problem by the Independent Safety Committee, as part of good clinical practice procedures.

"In Brazil, the inclusion of the first volunteer in the study occurred on Oct. 9 and new inclusions can only occur when there is authorization from Anvisa, which will proceed with the analysis of the research data and decide on the continuity or permanent suspension based on the safety and risk/benefit assessment," the agency said.

Janssen-Cilag received authorization from Anvisa in August to carry out the trials in Brazil.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.